Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
Kafka M, Giannini G, Artamonova N, Neuwirt H, Ofner H, Kramer G, Bauernhofer T, Luger F, Höfner T, Loidl W, Griessner H, Lusuardi L, Bergmaier A, Berger A, Winder T, Weiss S, Bauinger S, Krause S, Drerup M, Heinrich E, Schneider M, Madersbacher S, Vallet S, Stoiber F, Laimer S, Hruby S, Schachtner G, Nagele U, Lenart S, Ponholzer A, Pfuner J, Wiesinger C, Kamhuber C, Müldür E, Bektic J, Horninger W, Heidegger I. Kafka M, et al. Among authors: vallet s. Clin Genitourin Cancer. 2024 Apr;22(2):458-466.e1. doi: 10.1016/j.clgc.2023.12.018. Epub 2024 Jan 4. Clin Genitourin Cancer. 2024. PMID: 38267304 Free article.
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.
Niedersuess-Beke D, Mayrhofer K, Krauter J, Schnabel S, Gampenrieder SP, Miechowiecki J, Kiesl D, Luger F, Pfuner J, Wiesinger C, Vallet S, Andalibi H, Vais D, Banner A, Stoiber F, Spielgelberg J, Barth D, Bauernhofer T, Aufderklamm S, Weibrecht S, Mühlmann J, Mayer M, Hilbe W, Boulmé F, Klinglmair G, Heintel D, Shariat SF, Pichler M, Pichler R. Niedersuess-Beke D, et al. Among authors: vallet s. Clin Genitourin Cancer. 2024 Nov 22:102278. doi: 10.1016/j.clgc.2024.102278. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39672785 Free article.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Pleyer L, Vaisband M, Drost M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, Hartmann B, Petzer A, Schreder M, Schmitt CA, Vallet S, Melchardt T, Zebisch A, Pichler P, Zaborsky N, Machherndl-Spandl S, Wolf D, Keil F, Hasenauer J, Larcher-Senn J, Greil R. Pleyer L, et al. Among authors: vallet s. Am J Hematol. 2023 Nov;98(11):1685-1698. doi: 10.1002/ajh.27046. Epub 2023 Aug 7. Am J Hematol. 2023. PMID: 37548390 Free article.
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Gassner T, Chittilappilly C, Pirich T, Neuditschko B, Hackner K, Lind J, Aksoy O, Graichen U, Klee S, Herzog F, Wiesner C, Errhalt P, Pecherstorfer M, Podar K, Vallet S. Gassner T, et al. Among authors: vallet s. J Immunother Cancer. 2024 May 3;12(5):e008669. doi: 10.1136/jitc-2023-008669. J Immunother Cancer. 2024. PMID: 38702145 Free PMC article.
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer L, Heibl S, Tinchon C, Vallet S, Schreder M, Melchardt T, Stute N, Föhrenbach Quiroz KT, Leisch M, Egle A, Scagnetti L, Wolf D, Beswick R, Drost M, Larcher-Senn J, Grochtdreis T, Vaisband M, Hasenauer J, Zaborsky N, Greil R, Stauder R. Pleyer L, et al. Among authors: vallet s. Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388. Cancers (Basel). 2023. PMID: 36900181 Free PMC article.
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.
Fourati S, Reslan A, Bourret J, Casalegno JS, Rahou Y, Chollet L, Pillet S, Tremeaux P, Dossou NC, Gault E, Salmona M, Imbert-Marcille BM, Mirand A, Larrat S, Moisan A, Marot S, Schnuriger A, Veyrenche N, Engelmann I, Handala L, Henry A, Stephan V, Brichler S, Avettand-Fenoel V, Zemali N, Lefeuvre C, Pronier C, Deroche L, Jaffar-Bandjee MC, Mouna L, Francois C, Regueme A, Hartard C, Rogez S, Gallais F, Ly A, Rodriguez C, Dos Santos G, Simon-Loriere E, Schwartz O, Buchrieser J, Pawlotsky JM, Lemoine F, Audureau E, Rameix-Welti MA; POLYRES investigators. Fourati S, et al. Lancet Infect Dis. 2024 Oct 14:S1473-3099(24)00570-X. doi: 10.1016/S1473-3099(24)00570-X. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39419046
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024.
de Prost N, Audureau E, Guillon A, Handala L, Préau S, Guigon A, Uhel F, Le Hingrat Q, Delamaire F, Grolhier C, Tamion F, Moisan A, Darreau C, Thomin J, Contou D, Henry A, Daix T, Hantz S, Saccheri C, Giordanengo V, Pham T, Chaghouri A, Bay P, Pawlotsky JM, Fourati S; SEVARVIR investigators. de Prost N, et al. Ann Intensive Care. 2024 Jun 28;14(1):101. doi: 10.1186/s13613-024-01319-w. Ann Intensive Care. 2024. PMID: 38940865 Free PMC article.
183 results